Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Onyx

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Onyx's 2012 oncology sales performance.

Onyx Pharmaceuticals, Inc.

Amgen granted priority review for extended use of Kyprolis

Amgen granted priority review for extended use of Kyprolis $10.4bn that Amgen paid Kyprolis' developer Onyx Pharmaceuticals in 2013.

Takeda's ixazomib moves closer to US approval

Takeda's ixazomib moves closer to US approval If approved it could provide patients with an alternative to injectable proteasome inhibitors such as Takeda's own Velcade (bortezomib) and Amgen and Onyx' Kyprolis (carfilzomib). ... The FDA's decision comes after ixazomib was also given accelerated

Takeda files 'oral Velcade' for myeloma in US

Takeda files 'oral Velcade' for myeloma in US Takeda is starting to build a lead over rival Amgen/Onyx' orally-active oprozomib, which is currently in phase II trials in myeloma. ... The drug has some dose-limiting gastrointestinal toxicity that Amgen and Onyx are working to address by tweaking its

Amgen gets quick US review for Kyprolis

Amgen gets quick US review for Kyprolis That level of sales performance will be needed to justify the $10.4bn Amgen paid for Kyprolis' developer Onyx Pharmaceuticals in 2013.

Amgen's Kyprolis tops Velcade in myeloma trial

Amgen's Kyprolis tops Velcade in myeloma trial Kyprolis' developer Onyx Pharmaceuticals in 2013.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...